Literature DB >> 7247382

Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis.

S Pancorbo, C Comty.   

Abstract

Teh pharmacokinetics of gentamicin were studied in seven chronic renal failure patients undergoing continuous ambulatory peritoneal dialysis. Patients received 100 mg of gentamicin in 2 liters of dialysate during an initial pass, and serum and dialysate samples were collected for gentamicin determination. Approximately 49% of the amount introduced into the peritoneal cavity was absorbed systemically during a 6-h cycle. Subsequent clearance of gentamicin from the serum occurred slowly with an elimination half-life of 36 h. Dialysis clearance of gentamicin during continuous ambulatory peritoneal dialysis was 2.94 ml/min.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7247382      PMCID: PMC181486          DOI: 10.1128/AAC.19.4.605

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Kinetic model for gentamicin dosing with the use of individual patient parameters.

Authors:  R J Sawchuk; D E Zaske; R J Cipolle; W A Wargin; R G Strate
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

2.  Peritonitis during continuous ambulatory peritoneal dialysis.

Authors:  J Rubin; W A Rogers; H M Taylor; E D Everett; B F Prowant; L V Fruto; K D Nolph
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

3.  Continuous ambulatory peritoneal dialysis.

Authors:  R P Popovich; J W Moncrief; K D Nolph; A J Ghods; Z J Twardowski; W K Pyle
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

  3 in total
  9 in total

1.  Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  B D Smeltzer; M S Schwartzman; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 2.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

3.  Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokinetics.

Authors:  J E Svirbely; A J Pesce; S Singh; E J O'Flaherty
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 4.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

5.  Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study).

Authors:  Julie M Varghese; Jason A Roberts; Steven C Wallis; Robert J Boots; Helen Healy; Robert G Fassett; Jeffrey Lipman; Dwarakanathan Ranganathan
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-14       Impact factor: 8.237

Review 6.  Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review.

Authors:  R Janknegt; C H Koks
Journal:  Pharm Weekbl Sci       Date:  1984-12-14

7.  Population Pharmacokinetics of Intraperitoneal Gentamicin and the Impact of Varying Dwell Times on Pharmacodynamic Target Attainment in Patients with Acute Peritonitis Undergoing Peritoneal Dialysis.

Authors:  Andras Farkas; Katerina Oikonomou; Mohammad Ghanbar; Phillip Villasurda; Julie Varghese; Jeffrey Lipman; Joseph Sassine; Dwarakanathan Ranganathan; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2021-12-13       Impact factor: 5.938

Review 8.  Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.

Authors:  Caspar J Hodiamont; Annemieke K van den Broek; Suzanne L de Vroom; Jan M Prins; Ron A A Mathôt; Reinier M van Hest
Journal:  Clin Pharmacokinet       Date:  2022-06-27       Impact factor: 5.577

9.  Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study.

Authors:  Dwarakanathan Ranganathan; Julie M Varghese; Robert G Fassett; Jeffrey Lipman; Vincent D'Intini; Helen Healy; Jason A Roberts
Journal:  BMC Nephrol       Date:  2009-12-16       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.